Top

Published in:

01-12-2021 | Graft-Versus-Host Disease | Original Article

Analysis of factors associated with patient-reported physical functioning scores at discharge of allogeneic hematopoietic stem cell transplantation patients: a cross-sectional study

Authors: Masanobu Murao, Ryota Hamada, Tadakazu Kondo, Junsuke Miyasaka, Michiko Yoshida, Honami Yonezawa, Yasuyuki Arai, Junya Kanda, Manabu Nankaku, Ryosuke Ikeguchi, Akifumi Takaori-Kondo, Shuichi Matsuda

Published in: Supportive Care in Cancer | Issue 12/2021

Abstract

Purpose

The purpose of this study was to clarify the independent factors related to patient-reported physical functioning (PF) scores at discharge of patients who underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT).

Methods

A total of 103 patients who underwent allo-HSCT were included in this cross-sectional study. As a screening method, a single regression analysis was conducted with the PF domain in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 at discharge as the dependent variable, and body mass index, adverse events related to HSCT, and objective physical functions as independent variables. Multiple regression analysis was performed with PF as the dependent variable and variables that passed the screening by single regression analysis and confounders as independent variables.

Results

The mean PF score at discharge of the patients was 76.5 (standard deviation: 15.2). Based on the results of screening by the single regression analysis, length of stay, infections (+ / −), acute graft-versus-host disease grade, brief fatigue inventory score (BFI), knee extensor strength, and 6-min walk distance (6MWD) were included in the multiple regression analysis. BFI (B = − 11.94, p < 0.001) and 6MWD (per 10 m) (B = 0.56, p = 0.001) were extracted as significant independent variables governing the PF at discharge in the multiple regression model (adjusted R² = 0.59).

Conclusion

Higher exercise tolerance and lower fatigue in patients who underwent allo-HSCT were associated independently with patient-reported better PF scores at discharge.

Available only for authorised users

Gooley TA, Chien JW, Pergam SA et al (2010) Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med 363:2091–2101. https://doi.org/10.1056/NEJMoa1004383CrossRefPubMedPubMedCentral

Wingard JR, Majhail NS, Brazauskas R et al (2011) Long-term survival and late deaths after allogeneic hematopoietic cell transplantation. J Clin Oncol 29:2230–2239. https://doi.org/10.1200/jco.2010.33.7212CrossRefPubMedPubMedCentral

Kim I, Koh Y, Shin D et al (2020) Importance of monitoring physical function for quality of life assessments in hematopoietic stem cell transplantation patients: a prospective cohort study. In Vivo 34(2):771–777CrossRef

Cocks K, King MT, Velikova G, St-James MM, Fayers PM, Brown JM (2011) Evidence-based guidelines for determination of sample size and interpretation of the european organisation for the research and treatment of cancer quality of life questionnaire core 30. J Clin Oncol 29:89–96. https://doi.org/10.1200/jco.2010.28.0107CrossRefPubMed

Grulke N, Albani C, Bailer H (2012) Quality of life in patients before and after haematopoietic stem cell transplantation measured with the european organization for research and treatment of cancer (EORTC) quality of life core questionnaire QLQ-C30. Bone Marrow Transplant 47:473–482. https://doi.org/10.1038/bmt.2011.107CrossRefPubMed

Devins GM, Mah K, Messner HA et al (2018) Quality of life trajectories during the first year following hematopoietic cell transplantation: an inception cohort study. Support Care Cancer 26(7):2379–2386. https://doi.org/10.1007/s00520-018-4059-7CrossRefPubMed

Mosher CE, Redd WH, Rini CM, Burkhalter JE, DuHamel KN (2009) Physical, psychological, and social sequelae following hematopoietic stem cell transplantation: a review of the literature. Psychooncology 18:113–127. https://doi.org/10.1002/pon.1399CrossRefPubMedPubMedCentral

Pidala J, Anasetti C, Jim H (2009) Quality of life after allogeneic hematopoietic cell transplantation. Blood 114:7–19. https://doi.org/10.1182/blood-2008-10-182592CrossRefPubMedPubMedCentral

Wiskemann J, Dreger P, Schwerdtfeger R et al (2011) Effects of a partly self-administered exercise program before, during, and after allogeneic stem cell transplantation. Blood 117:2604–2613. https://doi.org/10.1182/blood-2010-09-306308CrossRefPubMed

10.

Morishita S, Kaida K, Ikegame K et al (2012) Impaired physiological function and health-related QOL in patients before hematopoietic stem-cell transplantation. Support Care Cancer 20:821–829. https://doi.org/10.1007/s00520-011-1156-2CrossRefPubMed

11.

Fiuza-Luces C, Simpson RJ, Ramírez M, Lucia A, Berger NA (2016) Physical function and quality of life in patients with chronic GvHD: a summary of preclinical and clinical studies and a call for exercise intervention trials in patients. Bone Marrow Transplant 51:13–26. https://doi.org/10.1038/bmt.2015.195CrossRefPubMed

12.

Kurosawa S, Oshima K, Yamaguchi T, Yanagisawa A et al (2017) Quality of life after allogeneic hematopoietic cell transplantation according to affected organ and severity of chronic graft-versus-host disease. Biol Blood Marrow Transplant 23:1749–1758. https://doi.org/10.1016/j.bbmt.2017.06.011CrossRefPubMed

13.

Morishita S, Tsubaki A, Hotta K et al (2019) The benefit of exercise in patients who undergo allogeneic hematopoietic stem cell transplantation. J Int Soc Phys Rehabil Med 2(1):54–61. https://doi.org/10.4103/jisprm.jisprm_2_19CrossRefPubMedPubMedCentral

14.

Boşnak Güçlü M, Barğı G, Sucak GT (2019) Impairments in dyspnea, exercise capacity, physical activity and quality of life of allogeneic hematopoietic stem cell transplantation survivors compared with healthy individuals: a cross sectional study. Physiother Theory Pract 8:1–12. https://doi.org/10.1080/09593985.2019.1594473CrossRef

15.

The WHOQOL Group (1998) Development of the world health organization WHOQOL-BREF quality of life assessment. Psychol Med 28(3):551–558. https://doi.org/10.1017/s0033291798006667CrossRef

16.

Panzini RG, Mosqueiro BP, Zimpel RR et al (2017) Quality-of-life and spirituality. Int Rev Psychiatry 29(3):263–282. https://doi.org/10.1080/09540261.2017.1285553CrossRefPubMed

17.

Pidala J, Chai X, Martin P et al (2013) Hand grip strength and 2-minute walk test in chronic graft-versus-host disease assessment: analysis from the chronic GVHD consortium. Biol Blood Marrow Transplant 19(6):967–972. https://doi.org/10.1016/j.bbmt.2013.03.014CrossRefPubMedPubMedCentral

18.

Morishita S, Kaida K, Yamauchi S et al (2013) Gender differences in health-related quality of life, physical function and psychological status among patients in the early phase following allogeneic haematopoietic stem cell transplantation. Psychooncology 22(5):1159–1166. https://doi.org/10.1002/pon.3128CrossRefPubMed

19.

Ware JE Jr, Sherbourne CD (1992) The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 30(6):473–483. https://doi.org/10.1007/BF03260127CrossRefPubMed

20.

Shaw BE (2019) Graft versus host disease clinical trials: is it time for patients centered outcomes to be the primary objective? Curr Hematol Malig Rep 14(1):22–30. https://doi.org/10.1007/s11899-019-0494-xCrossRefPubMedPubMedCentral

21.

Kobayashi K, Takeda F, Teramukai S et al (1998) A cross-validation of the european organization for research and treatment of cancer QLQ-C30 (EORTC QLQ-C30) for Japanese with lung cancer. Eur J Cancer 34(6):810–815. https://doi.org/10.1016/s0959-8049(97)00395-xCrossRefPubMed

22.

Fayers P, Aaronson N, Bjordal K, et al. (2001) EORTC QLQ-C30 scoring manual (ed 3). EORTC publications

23.

Mendoza TR, Wang XS, Cleeland CS et al (1999) The rapid assessment of fatigue severity in cancer patients: use of the brief fatigue inventory. Cancer 85(5):1186–1196. https://doi.org/10.1002/(sici)1097-0142(19990301)85:5%3c1186::aid-cncr24%3e3.0.co;2-nCrossRefPubMed

24.

Okuyama T, Wang XS, Akechi T et al (2003) Validation study of the Japanese version of the brief fatigue inventory. J Pain Symptom Manage 25(2):106–117. https://doi.org/10.1016/s0885-3924(02)00596-1CrossRefPubMed

25.

Nankaku M, Tsuboyama T, Akiyama H et al (2013) Preoperative prediction of ambulatory status at 6 months after total hip arthroplasty. Phys Ther 93(1):88–93. https://doi.org/10.2522/ptj.20120016CrossRefPubMed

26.

Nankaku M, Akiyama H, Kakinoki R et al (2014) Factors associated with ambulatory status 6 months after total hip arthroplasty. Physiotherapy 100(3):263–267. https://doi.org/10.1016/j.physio.2013.06.004CrossRefPubMed

27.

ATS statement, (2002) Guidelines for the six-minute walk test. Am J Respir Crit Care Med 166(1):111–117. https://doi.org/10.1164/ajrccm.166.1.at1102CrossRef

28.

Danaher EH, Ferrans C, Verlen E et al (2006) Fatigue and physical activity in patients undergoing hematopoietic stem cell transplant. Oncol Nurs Forum 33(3):614–624. https://doi.org/10.1188/06.Onf.614-624CrossRefPubMed

29.

Morishita S, Kaida K, Tanaka T et al (2012) Prevalence of sarcopenia and relevance of body composition, physiological function, fatigue, and health-related quality of life in patients before allogeneic hematopoietic stem cell transplantation. Support Care Cancer 20(12):3161–3168. https://doi.org/10.1007/s00520-012-1460-5CrossRefPubMed

30.

Mohty B, Mohty M (2011) Long-term complications and side effects after allogeneic hematopoietic stem cell transplantation: an update. Blood Cancer J 1(4):e16. https://doi.org/10.1038/bcj.2011.14CrossRefPubMedPubMedCentral

31.

Takekiyo T, Dozono K, Mitsuishi T et al (2016) Recovery of physical function and quality of life in patients undergoing hematopoietic stem cell transplantation: a 1-year follow-up. Bone Marrow Transplant 51(8):1127–1130. https://doi.org/10.1038/bmt.2016.58CrossRefPubMed

32.

Wakasugi T, Morishita S, Kaida K et al (2018) Impaired skeletal muscle oxygenation following allogeneic hematopoietic stem cell transplantation is associated with exercise capacity. Support Care Cancer 26(7):2149–2160. https://doi.org/10.1007/s00520-017-4036-6CrossRefPubMed

33.

Morishita S, Wakasugi T, Kaida K et al (2018) Fatigue, muscle oxygen consumption and blood flow to the skeletal muscle after allogeneic hematopoietic stem cell transplantation. Adv Exp Med Biol 1072:293–298CrossRef

34.

Stretton CM, Latham NK, Carter KN et al (2006) Determinants of physical health in frail older people: the importance of self-efficacy. Clin Rehabil 20(4):357–366. https://doi.org/10.1191/0269215506cr946oaCrossRefPubMed

35.

van Haren IE, Timmerman H, Potting CM et al (2013) Physical exercise for patients undergoing hematopoietic stem cell transplantation: systematic review and meta-analyses of randomized controlled trials. Phys Ther 93(4):514–528. https://doi.org/10.2522/ptj.20120181CrossRefPubMed

36.

Wiskemann J, Kleindienst N, Kuehl R et al (2015) Effects of physical exercise on survival after allogeneic stem cell transplantation. Int J Cancer 137(11):2749–2756. https://doi.org/10.1002/ijc.29633CrossRefPubMed

37.

Hamada R, Kondo T, Murao M et al (2020) Effect of the severity of acute graft-versus-host disease on physical function after allogeneic hematopoietic stem cell transplantation. Support Care Cancer 28(7):3189–3196. https://doi.org/10.1007/s00520-019-05124-1CrossRef

Title: Analysis of factors associated with patient-reported physical functioning scores at discharge of allogeneic hematopoietic stem cell transplantation patients: a cross-sectional study
Authors: Masanobu Murao
Ryota Hamada
Tadakazu Kondo
Junsuke Miyasaka
Michiko Yoshida
Honami Yonezawa
Yasuyuki Arai
Junya Kanda
Manabu Nankaku
Ryosuke Ikeguchi
Akifumi Takaori-Kondo
Shuichi Matsuda
Publication date: 01-12-2021
Publisher: Springer Berlin Heidelberg
Keywords: Graft-Versus-Host Disease
Graft-Versus-Host Disease
Fatigue
Stem Cell Transplantation
Stem Cell Transplantion
Stem Cell Transplantation
Published in: Supportive Care in Cancer / Issue 12/2021
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-021-06323-5

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 12/2021

Reducing pain in children with cancer at home: a feasibility study of the KLIK pain monitor app

Prevalence and correlates of psychological distress, unmet supportive care needs, and fear of cancer recurrence among haematological cancer patients during the COVID-19 pandemic

Fertility discussions in young adult stage III colorectal cancer population: a single-center institution experience

The application of “Omics” to accelerate precision medicine in Supportive Care in Cancer

Gabapentin enhances the antinociceptive effect of intrathecal morphine in refractory cancer pain patients

Association of co-morbidities with financial hardship in survivors of adult cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer